Key result
Multifactorial risk reduction via lifestyle and pharmacotherapy lowers cardiovascular events in type 2 diabetes.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with several cardiovascular (CV) risk factors such as insulin resistance, obesity, hypertension, dyslipidaemia, non-alcoholic fatty liver disease as well as platelet and haemostatic abnormalities increasing the risk of thrombosis. Therefore, T2DM patients are at an increased risk for CV disease (CVD). Areas covered: This narrative review discusses the treatment of T2DM. This includes lifestyle measures (diet, exercise and smoking cessation) as well as hypolipidaemic, antihypertensive, weight reducing, antiplatelet and glucose lowering drugs. The focus is on the effects of these therapeutic strategies on CVD risk. Randomized controlled clinical trials (RCTs) reporting CVD outcomes with such drugs in T2DM patients are also reviewed. Expert opinion: Apart from current guidelines, the findings of RCTs on CVD outcomes in T2DM patients should be taken into consideration in daily clinical practice. Multiple risk factors should be targeted simultaneously in such high-risk patients in order to efficiently reduce the risk of CV events.
No takes yet. Share an insight, caveat, or question.
Katsiki et al. (2017) conducted a review in Type 2 diabetes mellitus. Lifestyle measures and hypolipidaemic, antihypertensive, weight-reducing, antiplatelet, and glucose-lowering drugs was evaluated on Cardiovascular disease risk and events. Simultaneous targeting of multiple cardiovascular risk factors through lifestyle and pharmacotherapy is recommended to reduce cardiovascular events in type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: